MiMedx Group, Inc.
| Nasdaq: MDXG
MiMedx Group, Inc. is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFix and its tissue technologies, AmnioFix and EpiFix. The tissue technologies, processed from the human amniotic membrane, utilize its proprietary Purion process that was developed by its wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. The company was founded on July 30, 1985 and is headquartered in Kennesaw, GA.